Support Group

Gene therapy is emerging as a groundbreaking and potentially curative approach for Age-Related Macular Degeneration (AMD), offering a glimmer of hope for a sustained and long-term solution. The traditional treatment for wet AMD, which involves frequent anti-VEGF injections, can be burdensome for patients. Gene therapy aims to solve this by delivering a viral vector carrying a gene that codes for an anti-VEGF protein directly into the eye. The retinal cells then begin to produce the therapeutic protein on their own, providing a continuous supply of the drug and potentially eliminating the need for regular injections. This revolutionary approach not only improves patient convenience and compliance but could also lead to better clinical outcomes by maintaining a consistent therapeutic level of the drug in the eye. Research is also underway to use gene therapy to address the root causes of dry AMD, such as complement system dysfunction. The goal is to correct the genetic defects or to deliver therapeutic proteins that can protect retinal cells from damage. While still in its early stages of development, gene therapy has the potential to transform the AMD market from one focused on chronic management to one that offers a long-term, possibly even a single-dose, treatment. The success of these therapies could create a new and highly valuable segment within the market. For an in-depth analysis of this exciting area of research, you can refer to the comprehensive Age-Related Macular Degeneration Market report.